相关实验视频

Updated: Jun 14, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

对于局部晚期子宫癌中耐治疗亚型的分子和细胞点的蛋白质基因组学表征

Do Young Hyeon¹, Dowoon Nam², Hye-Jin Shin³

¹School of Biological Sciences, Seoul National University, Seoul, 08826, Republic of Korea.

Molecular cancer

|March 15, 2025

概括

蛋白质基因组分析揭示了局部晚期宫癌 (LACC) 的不同亚型. 某些亚型 (Sub3,5,6) 呈现治疗耐药性,由特定的分子变化和细胞通路驱动,提供潜在的治疗点.

科学领域:

在瘤学瘤学.
蛋白质基因组学是什么
癌症生物学癌症生物学

背景情况:

局部晚期宫癌 (LACC) 在治疗和预后方面存在复杂的挑战.
了解LACC的分子异质性对于开发向疗法至关重要.

研究的目的:

对LACC进行全面的蛋白质基因组分析.
确定LACC的不同分子亚型及其与治疗耐药性的关联.
为了发现抗性LACC亚型的潜在治疗点.

主要方法:

外体序列测序 (Exome-seq) 用于识别遗传变化.
对mRNA,蛋白质和酸化数据的综合分析.
聚类分析以定义LACC亚型.
研究特定基因突变 (例如,CIC) 和它们的下游影响.

主要成果:

鉴定了六种LACC亚型 (亚型1-6) 与亚型3,5,6显示生存率差和耐治疗性.
Sub3的特点是免疫和细胞外基质 (ECM) 激活.
亚5表现出上皮层-介质细胞转换 (EMT) 和免疫感冒特征.
亚6显示增加了与O相关的糖化,这是腺-LACC的特征.
与通过ETV4激活EMT相关的CIC突变;通过ETV4激活EMT相关的CIC突变;在Sub5.5中涉及T细胞抑制的高PVR和骨髓原抑制细胞.

结论:

蛋白质基因组分析界定了耐治疗的LACC亚型.
特定的分子通路 (角质化,O-糖化,EMT,免疫检查点) 与LACC亚型相关.
已识别的细胞参与者和突变为LACC提供了潜在的生物标志物和治疗点.

关键词:

和治疗耐药性的治疗.癌症亚型的分类局部晚期的子宫癌.蛋白质基因组学是什么

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...